Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 3/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MITF | O75030 | 1/20 | 0.38 |
| ▸ | XBP1 | P17861 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.38 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.38 |
| ▸ | F12 | P00748 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21639618 | 0.87 | LCK (0.41) | DYRK1ADYRK1BKDRKCNH2KDM4E | |
| SCHEMBL21639781 | 0.86 | BRD4 (0.40) | DYRK1ADYRK1BKDR | |
| SCHEMBL23066443 | 0.85 | NSD2 (0.50) | DYRK1ADYRK1BNPC1RAB9AF12 | |
| SCHEMBL21639580 | 0.85 | KCNH2 (0.52) | KCNH2 | |
| SCHEMBL21639564 | 0.84 | MAOA (0.50) | KCNH2 | |
| SCHEMBL21639644 | 0.83 | CA12 (0.48) | KCNH2NPC1RAB9A | |
| SCHEMBL21639509 | 0.82 | TSHR (0.52) | KDM4ENPC1RAB9A | |
| SCHEMBL21639643 | 0.81 | MAPK7 (0.44) | KCNH2NPC1RAB9A | |
| SCHEMBL21639472 | 0.80 | BRD4 (0.46) | KCNH2KDM4E | |
| SCHEMBL23078852 | 0.79 | DYRK1A (0.46) | DYRK1ADYRK1BKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210070747-A1 | 2(1H)-QUINOLINONE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2021-03-11 | — | — | US | disclosed |
| US-20210070747-A1 | 2(1H)-QUINOLINONE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2021-03-11 | — | — | US | disclosed |
| EP-3604281-A1 | 2(1H)-QUINOLINONE DERIVATIVE | Taisho Pharmaceutical Co., Ltd. (JP) | 2020-02-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070747-A1 | 2(1H)-QUINOLINONE DERIVATIVE | TOP2A, TOP2B, TOP1 | DYRK1A 2208/4885DYRK1B 1726/4885KDR 4549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.